Dincer, N. Et Al. 2023. Neoadjuvant mFOLFIRINOX vs mFOLFIRINOX Plus Radiotherapy in Patients With Borderline Resectable Pancreatic Cancer-The A021501 Trial. JAMA ONCOLOGY , vol.9, no.2 , 276-277.

Dincer, N., UĞURLUER, G., & ÖZYAR, E., (2023). Neoadjuvant mFOLFIRINOX vs mFOLFIRINOX Plus Radiotherapy in Patients With Borderline Resectable Pancreatic Cancer-The A021501 Trial. JAMA ONCOLOGY , vol.9, no.2, 276-277.

Dincer, Neris, Gamze UĞURLUER, And ENİS ÖZYAR. "Neoadjuvant mFOLFIRINOX vs mFOLFIRINOX Plus Radiotherapy in Patients With Borderline Resectable Pancreatic Cancer-The A021501 Trial," JAMA ONCOLOGY , vol.9, no.2, 276-277, 2023

Dincer, Neris Et Al. "Neoadjuvant mFOLFIRINOX vs mFOLFIRINOX Plus Radiotherapy in Patients With Borderline Resectable Pancreatic Cancer-The A021501 Trial." JAMA ONCOLOGY , vol.9, no.2, pp.276-277, 2023

Dincer, N. UĞURLUER, G. And ÖZYAR, E. (2023) . "Neoadjuvant mFOLFIRINOX vs mFOLFIRINOX Plus Radiotherapy in Patients With Borderline Resectable Pancreatic Cancer-The A021501 Trial." JAMA ONCOLOGY , vol.9, no.2, pp.276-277.

@article{article, author={Neris Dincer Et Al. }, title={Neoadjuvant mFOLFIRINOX vs mFOLFIRINOX Plus Radiotherapy in Patients With Borderline Resectable Pancreatic Cancer-The A021501 Trial}, journal={JAMA ONCOLOGY}, year=2023, pages={276-277} }